Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182073 · ClinicalTrials.gov registry record · Phase 1
FT576 in Subjects With Multiple Myeloma
A Phase 1 study, sponsored by Fate Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT05182073: Completed Phase 1 study, sponsored by Fate Therapeutics.
NCT05182073 is a Phase 1 study that has completed, run by Fate Therapeutics. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05182073, a Phase 1 study, has completed, sponsored by Fate Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Daratumumab
- DRUG Bendamustine
- DRUG FT576 (Allogenic CAR NK cells with BCMA expression)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 1 |
What the finished NCT05182073 record still lists
NCT05182073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05182073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05182073 about?
NCT05182073 is a clinical study titled "FT576 in Subjects With Multiple Myeloma". This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
What is the current status of trial NCT05182073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2021-11-10. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT05182073?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Daratumumab (DRUG), Bendamustine (DRUG), FT576 (Allogenic CAR NK cells with BCMA expression) (DRUG).
Who is sponsoring clinical trial NCT05182073?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05182073's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI